Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors

Clinica Chimica Acta

Volumn 368, Issue 1-2, 2006, Pages 138-143

  Orbe, J ^a   Beloqui, O ^b   Rodriguez, J A ^a   Belzunce, M S ^a   Roncal, C ^a   Paramo J A ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Atherosclerosis; COX 2 polymorphism; Hypercholesterolemia; Inflammation

Indexed keywords

C REACTIVE PROTEIN; CYCLOOXYGENASE 2; FIBRINOGEN; INTERLEUKIN 6; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DEMOGRAPHY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; MULTIPLE REGRESSION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL; CYCLOOXYGENASE 2; CYSTEINE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GLYCINE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MONOCYTES; POLYMORPHISM, GENETIC;

EID: 33646827887     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2005.12.019     Document Type: Article

References (34)

1. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
2. Turini M.E., and DuBois R.N. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 53 (2002) 35-57
3. Smith W.L., and Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 107 (2001) 1491-1495
4. Tanabe T., and Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 68-69 (2002) 95-114
5. Prescott S.M., and Fitzpatrick F.A. Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470 (2000) M69-M78
6. Pisetsky D.S., and St. Clair E.W. Progress in the treatment of rheumatoid arthritis. JAMA 286 (2001) 2787-2790
7. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 68-69 (2002) 165-175
8. Baker C.S., Hall R.J., Evans T.J., et al. Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler Thromb Vasc Biol 19 (1999) 646-655
9. Schonbeck U., Sukhova G.K., Graber P., Coulter S., and Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 155 (1999) 1281-1291
10. Cipollone F., Fazia M., Iezzi A., et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation 107 (2003) 1479-1485
11. Paramo J.A., Rodriguez J.A., Beloqui O., and Orbe J. Monocyte cyclooxygenase-2 activity: a new therapeutic target for atherosclerosis?. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 303-311
12. Beloqui O., Paramo J.A., Orbe J., et al. Monocyte cyclooxygenase-2 overactivity: a new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?. Eur Heart J 26 (2005) 153-158
13. Adderley S.R., and Fitzgerald D.J. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 274 (1999) 5038-5046
14. Shinmura K., Tang X.L., Wang Y., et al. Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci U S A 97 (2000) 10197-10202
15. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., and Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5 (1999) 698-701
16. Fritsche E., Baek S.J., King L.M., Zeldin D.C., Eling T.E., and Bell D.A. Functional characterization of cyclooxygenase-2 polymorphisms. J Pharmacol Exp Ther 299 (2001) 468-476
17. Papafili A., Hill M.R., Brull D.J., et al. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22 (2002) 1631-1636
18. Cipollone F., Toniato E., Martinotti S., et al. A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA 291 (2004) 2221-2228
19. Paramo J.A., Orbe J., Beloqui O., et al. Prothrombin fragment 1 + 2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease. Stroke 35 (2004) 1085-1089
20. Smith L.H., Boutaud O., Breyer M., Morrow J.D., Oates J.A., and Vaughan D.E. Cyclooxygenase-2-dependent prostacyclin formation is regulated by low density lipoprotein cholesterol in vitro. Arterioscler Thromb Vasc Biol 22 (2002) 983-988
21. Norata G.D., Pirillo A., Pellegatta F., Inoue H., and Catapano A.L. Native LDL and oxidized LDL modulate cyclooxygenase-2 expression in HUVECs through a p38-MAPK, NF-kappaB, CRE dependent pathway and affect PGE2 synthesis. Int J Mol Med 14 (2004) 353-359
22. Abdullah L, Ait-Ghezala G, Crawford F, et al. The cyclooxygenase 2 - 765C promoter allele is a protective factor for Alzheimer's disease. Neurosci Lett 2005 (Nov 2) (Electronic publication ahead of print).
23. Cipollone F., Prontera C., Pini B., et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104 (2001) 921-927
24. Mancini G.B., Dahlof B., and Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 109 (2004) IV22-IV30
25. Chambless L.E., Heiss G., Folsom A.R., et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 146 (1997) 483-494
26. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
27. Linton M.F., and Fazio S. Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 4 (2004) 116-123
28. Bogaty P., Brophy J.M., Noel M., et al. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study. Circulation 110 (2004) 934-939
29. Monakier D., Mates M., Klutstein M.W., et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. Chest 125 (2004) 1610-1615
30. Williams J.A., and Shacter E. Regulation of macrophage cytokine production by prostaglandin E2. Distinct roles of cyclooxygenase-1 and -2. J Biol Chem 272 (1997) 25693-25699
31. Humphries S.E., Luong L.A., Ogg M.S., Hawe E., and Miller G.J. The interleukin-6 - 174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 22 (2001) 2243-2252
32. Li S.P., and Goldman N.D. Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry 35 (1996) 9060-9068
33. Paramo J.A., Beloqui O., Colina I., Diez J., and Orbe J. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects. J Thromb Haemost 3 (2005) 662-664
34. Yamagata K., Matsumura K., Inoue W., et al. Coexpression of microsomal-type prostaglandin E synthase with cyclooxygenase-2 in brain endothelial cells of rats during endotoxin-induced fever. J Neurosci 21 (2001) 2669-2677